Navigation Links
The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch of Novel Therapies
Date:8/20/2013

BURLINGTON, Mass., Aug. 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the dyslipidemia market will grow to just over $31 billion in 2022, at an annual rate of 2 percent from 2012. The launch of antidyslipidemic agents from two novel drug classes–PCSK9 and CETP inhibitors–will be the primary drivers of market growth, off-setting the voracious genericization that has and will continue to impact the market through 2022.

The Pharmacor advisory service entitled Dyslipidemia finds that, despite continued generic erosion of Pfizer's Lipitor (atorvastatin) and the launch of generic versions of AstraZeneca's/Shionogi's Crestor and Merck's ezetimibe franchise—Zetia (ezetimibe), Vytorin (ezetimibe/simvastatin), Liptruzet (ezetimibe/atorvastatin)—statins will remain the sales-leading drug class through 2022.

"The failure of non-statin drugs to demonstrate a cardiovascular outcomes benefit above that of statin therapy in clinical trial has further cemented the first-line status of the statin class, and eroded physician willingness to address residual risk by normalizing non-LDL lipids," said Decision Resources Analyst Pam Narang, M.Sc., Ph.D. "Decision Resources expects the recent outcome of the HPS2-THRIVE study that investigated the effect of HDL-C raising with Merck's Tredaptive to spell the end for niacin-based drugs.  Yet we see continued physician optimism for CETP inhibitors, which also primarily target HDL-C. While this enthusiasm is driven by their additional LDL-C lowering ability, the pendulum appears to be swinging back to LDL-C as the most robust modifiable dyslipidemia target, according to experts we interviewed."

The report findings also reveal the result of the outcomes trial IMPROVE-IT for ezetimibe is the most highly anticipated near-term event in the dyslipidemia market. Positive data from this trial will have a significant effect on physician prescribing and provide further validation of the LDL-C hypothesis, which will impact emerging LDL-C lowering agents such as the PCSK9 inhibitors. These agents will initially target the most high-risk patients. Launching in a specific patient subpopulation with the intention of gaining a broader label is an established development strategy, and one previously employed for prescription omega-3 fatty acids, Amarin's Vascepa and AstraZeneca's Epanova.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
2. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
3. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
5. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
6. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
7. Ophthalmic Drugs: World Market Prospects 2012-2022
8. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
9. ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report
10. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... July 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... for the second-quarter 2017 and updated financial guidance for ... Second-Quarter 2017 Highlights Reported net sales ... the prior-year quarter. Net sales at constant currency (organic) ... EPS was $0.51, compared to $0.60 in the prior-year ...
(Date:7/26/2017)... 2017  Radium Medical Aesthetics, a leading medical aesthetic clinic in ... by effectively addressing several skin conditions from the inside. ... and more fragile. The skin becomes more transparent due to the ... harmful UV rays from the sun contributes to aging skin, causing ... ...
(Date:7/26/2017)... The Galien Foundation announced today the 2017 11 ... Award Nominees. Counted among the global health innovation industry,s most ... technology product achievement that improves the human condition. ... be U.S. Food and Drug Administration (FDA) approved for market ... impact human health. Sales data are not considered by the ...
Breaking Medicine Technology:
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... says will lift the veil on false teachings pertaining to the mother of the Savior ... teach, you see a far different picture of the role of this historical woman. ...
(Date:8/18/2017)... ... 2017 , ... “Our Mountains to Climb: A Journey of Love and Faith ... together through the faith they shared to overcome struggles in life. “Our Mountains to ... author, Barbara J. Corcoran, a retired teacher and happily married since 1999; the author’s ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Depressed: Super Heroes of the ... to reflect upon the stories and the relevance these tales may have on the ... Jessica Linhart, a former special education teacher, Jessica spends much of her time enjoying ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Steve the Snake”: ... “Steve the Snake” is the creation of published author, Harold Flash Haskins Jr., a ... a Department of Defense police officer. , “I write moral-based short stories for children ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... announces that it will feature the National Council for Therapeutic Recreation Certification (NCTRC), ... information. , Established in 1981, NCTRC is a non-profit, international organization dedicated to ...
Breaking Medicine News(10 mins):